Plasma microRNA vary in association with the progression of Alzheimer's disease

Early intervention in Alzheimer's disease (AD) requires the development of an easily administered test that is able to identify those at risk. Focusing on microRNA robustly detected in plasma and standardizing the analysis strategy, we sought to identify disease‐stage specific biomarkers.

[1]  H. Zetterberg,et al.  A high‐performance biomarker panel for Alzheimer’s disease screening and staging identified by large‐scale plasma proteomic profiling , 2021, Alzheimer's & Dementia.

[2]  V. Mok,et al.  Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and staging , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[3]  W. Abraham,et al.  Plasma microRNA vary in association with the progression of Alzheimer’s disease , 2020 .

[4]  Bin Zhang,et al.  MicroRNA-195 rescues ApoE4-induced cognitive deficits and lysosomal defects in Alzheimer’s disease pathogenesis , 2020, Molecular Psychiatry.

[5]  Ning Chen,et al.  The Regulation of microRNAs in Alzheimer's Disease , 2020, Frontiers in Neurology.

[6]  Xiao-Li Yang,et al.  MiR-195 alleviates oxygen–glucose deprivation/reperfusion-induced cell apoptosis via inhibition of IKKα-mediated NF-κB pathway , 2020, The International journal of neuroscience.

[7]  Y. Asmann,et al.  Alzheimer’s Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways , 2020, Neuron.

[8]  Chen Li,et al.  miR‐29c‐3p inhibits microglial NLRP3 inflammasome activation by targeting NFAT5 in Parkinson's disease , 2020, Genes to cells : devoted to molecular & cellular mechanisms.

[9]  S. Luo,et al.  MiR-335-5p inhibits β-Amyloid (Aβ) accumulation to attenuate cognitive deficits through targeting c-jun-N-terminal kinase 3 in alzheimer's disease. , 2020, Current neurovascular research.

[10]  Chaur-Jong Hu,et al.  Clinical trials of new drugs for Alzheimer disease , 2020, Journal of Biomedical Science.

[11]  D. Kapogiannis.  Exosome Biomarkers Revolutionize Preclinical Diagnosis of Neurodegenerative Diseases and Assessment of Treatment Responses in Clinical Trials. , 2020, Advances in experimental medicine and biology.

[12]  A. Hill.  Extracellular Vesicles and Neurodegenerative Diseases , 2019, The Journal of Neuroscience.

[13]  R. Perneczky,et al.  Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid , 2019, Alzheimer's & Dementia.

[14]  J. Potashkin,et al.  Meta-Analysis of Gene Expression Changes in the Blood of Patients with Mild Cognitive Impairment and Alzheimer’s Disease Dementia , 2019, International journal of molecular sciences.

[15]  A. Ruiz,et al.  Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project , 2019, Alzheimer's & Dementia.

[16]  S. Kushner,et al.  A functional variant in the miR‐142 promoter modulating its expression and conferring risk of Alzheimer disease , 2019, Human mutation.

[17]  H. Tanila,et al.  Altered Insulin Signaling in Alzheimer’s Disease Brain – Special Emphasis on PI3K-Akt Pathway , 2019, Front. Neurosci..

[18]  K. Prasad.  AGE–RAGE stress: a changing landscape in pathology and treatment of Alzheimer’s disease , 2019, Molecular and Cellular Biochemistry.

[19]  Paula Desplats,et al.  Alterations in Striatal microRNA-mRNA Networks Contribute to Neuroinflammation in Multiple System Atrophy , 2019, Molecular Neurobiology.

[20]  Jee Hoon Roh,et al.  Comparative analyses of plasma amyloid-β levels in heterogeneous and monomerized states by interdigitated microelectrode sensor system , 2019, Science Advances.

[21]  Nicholas M. Wragg,et al.  Systematic Review of miRNA as Biomarkers in Alzheimer’s Disease , 2019, Molecular Neurobiology.

[22]  Jun Xu,et al.  Astrocytic miR-324-5p is essential for synaptic formation by suppressing the secretion of CCL5 from astrocytes , 2019, Cell Death & Disease.

[23]  Jantje Goerdten,et al.  Statistical methods for dementia risk prediction and recommendations for future work: A systematic review , 2019, Alzheimer's & dementia.

[24]  L. Schneider,et al.  Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need , 2018, Alzheimer's & Dementia.

[25]  D. Galasko,et al.  Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid. , 2019, Journal of Alzheimer's disease : JAD.

[26]  W. Abraham,et al.  Circulating Plasma microRNAs are Altered with Amyloidosis in a Mouse Model of Alzheimer's Disease. , 2018, Journal of Alzheimer's disease : JAD.

[27]  H. Brenner,et al.  The genetic risk of Alzheimer’s disease beyond APOE ε4: systematic review of Alzheimer’s genetic risk scores , 2018, Translational Psychiatry.

[28]  I. MacRae,et al.  Regulation of microRNA function in animals , 2018, Nature Reviews Molecular Cell Biology.

[29]  Carme Carrion,et al.  Cognitive Therapy for Dementia Patients: A Systematic Review , 2018, Dementia and Geriatric Cognitive Disorders.

[30]  L. Lannfelt,et al.  Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers , 2018, Acta Neuropathologica.

[31]  L. Watkins,et al.  MicroRNAs: Roles in Regulating Neuroinflammation , 2018, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[32]  He-kun Jin,et al.  The Long Non‐Coding RNA TP73‐AS1 Interacted With miR‐142 to Modulate Brain Glioma Growth Through HMGB1/RAGE Pathway , 2018, Journal of cellular biochemistry.

[33]  C. Rowe,et al.  Association of &bgr;-Amyloid and Apolipoprotein E &egr;4 With Memory Decline in Preclinical Alzheimer Disease , 2018, JAMA neurology.

[34]  Z. Minuchehr,et al.  Analysis of microRNA and Gene Expression Profiles in Alzheimer’s Disease: A Meta-Analysis Approach , 2018, Scientific Reports.

[35]  K. Blennow,et al.  The Past and the Future of Alzheimer’s Disease Fluid Biomarkers1 , 2018, Journal of Alzheimer's disease : JAD.

[36]  C. Rowe,et al.  High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.

[37]  J. Ai,et al.  MicroRNA-195 prevents dendritic degeneration and neuron death in rats following chronic brain hypoperfusion , 2017, Cell Death & Disease.

[38]  Chun Zhou,et al.  Lower Serum Levels of miR-29c-3p and miR-19b-3p as Biomarkers for Alzheimer's Disease. , 2017, The Tohoku journal of experimental medicine.

[39]  D. Centonze,et al.  miR-142-3p Is a Key Regulator of IL-1β-Dependent Synaptopathy in Neuroinflammation , 2017, The Journal of Neuroscience.

[40]  Julie A Saugstad,et al.  MicroRNAs in Human Cerebrospinal Fluid as Biomarkers for Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[41]  P. Reddy,et al.  MicroRNAs as Peripheral Biomarkers in Aging and Age-Related Diseases. , 2017, Progress in molecular biology and translational science.

[42]  D. Galasko,et al.  Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile , 2016, Alzheimer's & dementia.

[43]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[44]  Simone Lista,et al.  Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges , 2015, Alzheimer's & dementia.

[45]  Lars Bäckman,et al.  A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial , 2015, The Lancet.

[46]  K. Blennow,et al.  Amyloid biomarkers in Alzheimer's disease. , 2015, Trends in pharmacological sciences.

[47]  Yan Cheng,et al.  Downregulated miR-29c correlates with increased BACE1 expression in sporadic Alzheimer's disease. , 2015, International journal of clinical and experimental pathology.

[48]  C. Rowe,et al.  Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment , 2014, Molecular Psychiatry.

[49]  Zoltan Dezso,et al.  Circulating miRNA Biomarkers for Alzheimer's Disease , 2013, Alzheimer's & Dementia.

[50]  Edward Y. Chen,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[51]  T. Blondal,et al.  Assessing sample and miRNA profile quality in serum and plasma or other biofluids. , 2013, Methods.

[52]  J. Teng,et al.  MicroRNA-195 downregulates Alzheimer's disease amyloid-β production by targeting BACE1 , 2012, Brain Research Bulletin.

[53]  C. Rowe,et al.  Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition , 2012, Neurology.

[54]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[55]  B. Brüne,et al.  MicroRNA-27b Contributes to Lipopolysaccharide-mediated Peroxisome Proliferator-activated Receptor γ (PPARγ) mRNA Destabilization* , 2010, The Journal of Biological Chemistry.

[56]  A. Roses,et al.  Identification of miRNA Changes in Alzheimer's Disease Brain and CSF Yields Putative Biomarkers and Insights into Disease Pathways , 2008 .

[57]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[58]  Jiankun Cui,et al.  Hypoxia-inducible Factor 1 (HIF-1 )-mediated Hypoxia Increases BACE1 Expression and -Amyloid Generation* , 2007 .

[59]  R. Cappai,et al.  Packaging of prions into exosomes is associated with a novel pathway of PrP processing , 2007, The Journal of pathology.

[60]  K. Jin,et al.  Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[61]  J. Concato,et al.  A simulation study of the number of events per variable in logistic regression analysis. , 1996, Journal of clinical epidemiology.